NCT01628601View on ClinicalTrials.gov

GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Are Insufficiently Responsive to Monotherapy

CompletedOBSERVATIONAL

Enrollment

392

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions

Glaucoma, Open-AngleOcular Hypertension

Interventions

DRUG

Fixed combination 0.3 mg bimatoprost and 5 mg timolol

Patients with POAG or OHT prescribed GANfort® (fixed combination 0.3 mg bimatoprost and 5 mg timolol) treatment in a dose determined by the physician prior to study entry

Trial Locations (1)

Unknown

Vienna